Epoetin alfa biosimilar - Sandoz

Drug Profile

Epoetin alfa biosimilar - Sandoz

Alternative Names: Abseamed; Aczicrit; Binocrit; Epoetin alfa Hexal; Epoetin lambda - Sandoz; Grandicrit; HX 575; HX 575 epoetin alfa; HX 575, recombinant epoetin alfa; Novicrit

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sandoz
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 12 Feb 2015 Launched for Anaemia in Russia (SC)
  • 01 Jan 2015 Sandoz completes the phase III ACCESS trial for Anaemia in USA (NCT01693029)
  • 01 Oct 2014 Sandoz completes the phase III SENSE trial in Anaemia in Germany, Italy, Romania, Russia, Turkey, Ukraine and Poland (NCT01576341; EudraCT2011-002871-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top